Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07293403 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Name: Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas — clinical trial record (NCT07293403)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorCity of Hope Medical Center

Started2026-10-01

View on ClinicalTrials.gov ↗

Amendment history

2026-08-03

Study Status v2

Start date2026-06-07→2026-10-01

2026-05-29

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Study sitesdetails revised at 1 of 1 site

2025-12-17

Original filing

City of Hope Medical Center

385 trials monitored

See 43 trials at risk

Non-Hodgkin Lymphoma

1,512 trials monitored

See 79 trials at risk

This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy (maintenance) for patients with peripheral T-cell lymphomas. Duvelisib is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells.

Trial Details

NCT Number	NCT07293403
Lead Sponsor	City of Hope Medical Center Collaborators: National Cancer Institute (NCI)
Conditions	Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Enrollment	25 participants
Start Date	2026-10-01
Primary Completion	2027-11-23 (estimated)
Study Completion	2027-11-23 (estimated)
Updated on ClinicalTrials.gov	2026-08-05